Allegra Marketing Strategy “Drives On” In Response To Claritin Switch
This article was originally published in The Tan Sheet
Executive Summary
Aventis will not change its marketing strategy for Allegra following the Rx-to-OTC switch of Schering-Plough's Claritin
You may also be interested in...
Claritin Pollen Chaser Bus Campaign Drives Home Antihistamine Safety
Schering-Plough's Pollen Chaser marketing campaign for Claritin, breaking in time for the spring allergy season, focuses on the antihistamine's non-sedating characteristics
Allegra Ad State Law Portrayal Misleading When Applied To Benadryl – W-L
A DTC radio ad for Aventis' Rx antihistamine Allegra (fexofenadine) misrepresents state laws concerning driving impairment when referring to Pfizer/Warner-Lambert Consumer Group's Benadryl, the firm alleges in a case to appear in an upcoming NAD Case Reports
Sedating Drug “Operating Machinery” Warnings Need Clarification – FDAer
Label statements advising "use caution when operating machinery" do not adequately communicate the risks consumers face from potentially sedating or impairing drugs, an FDA rep said Nov. 15